Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $62.1 million.

  • Relay Therapeutics' Non-Current Assets fell 29.24% to $46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.0 million, marking a year-over-year decrease of 29.24%. This contributed to the annual value of $62.1 million for FY2024, which is 15.95% down from last year.
  • Per Relay Therapeutics' latest filing, its Non-Current Assets stood at $62.1 million for FY2024, which was down 15.95% from $73.9 million recorded in FY2023.
  • Relay Therapeutics' Non-Current Assets' 5-year high stood at $80.3 million during FY2022, with a 5-year trough of $29.7 million in FY2020.
  • For the 3-year period, Relay Therapeutics' Non-Current Assets averaged around $72.1 million, with its median value being $73.9 million (2023).
  • As far as peak fluctuations go, Relay Therapeutics' Non-Current Assets soared by 149.27% in 2022, and later decreased by 15.95% in 2024.
  • Yearly analysis of 5 years shows Relay Therapeutics' Non-Current Assets stood at $29.7 million in 2020, then rose by 8.32% to $32.2 million in 2021, then surged by 149.27% to $80.3 million in 2022, then fell by 7.96% to $73.9 million in 2023, then dropped by 15.95% to $62.1 million in 2024.